Bioventus Inc. (NYSE:BVS) CFO Sells $66,214.62 in Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 6,498 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $66,214.62. Following the completion of the sale, the chief financial officer now owns 118,817 shares of the company’s stock, valued at approximately $1,210,745.23. This trade represents a 5.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Mark Leonard Singleton also recently made the following trade(s):

• On Monday, December 23rd, Mark Leonard Singleton sold 10,733 shares of Bioventus stock. The shares were sold at an average price of $10.53, for a total transaction of $113,018.49.

Bioventus Stock Up 0.6 %

Shares of NYSE:BVS opened at $10.01 on Friday. The firm has a market cap of $812.36 million, a PE ratio of -16.41 and a beta of 0.85. The company has a fifty day simple moving average of $10.32 and a 200 day simple moving average of $10.85. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a 12-month low of $3.90 and a 12-month high of $14.38.

Analyst Ratings Changes

Several research analysts have recently weighed in on BVS shares. Canaccord Genuity Group upped their target price on shares of Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and boosted their price target for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Institutional Investors Weigh In On Bioventus

Hedge funds and other institutional investors have recently modified their holdings of the stock. HighTower Advisors LLC lifted its position in shares of Bioventus by 11.3% during the fourth quarter. HighTower Advisors LLC now owns 13,617 shares of the company’s stock worth $143,000 after purchasing an additional 1,380 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Bioventus by 9.4% during the 4th quarter. Principal Financial Group Inc. now owns 19,228 shares of the company’s stock worth $202,000 after buying an additional 1,652 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Bioventus by 106.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company’s stock worth $36,000 after acquiring an additional 1,786 shares in the last quarter. EP Wealth Advisors LLC grew its position in shares of Bioventus by 17.0% in the 4th quarter. EP Wealth Advisors LLC now owns 14,096 shares of the company’s stock worth $148,000 after acquiring an additional 2,047 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Bioventus by 26.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,194 shares of the company’s stock valued at $160,000 after acquiring an additional 3,153 shares during the last quarter. Institutional investors own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.